The 10 Best-Selling Drugs Of The Year

Ten best-selling drugs in 2017
Ten best-selling drugs in 2017

Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year.

A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV or HCV infections.

According to insurance industry group America’s Health Insurance Programs or AHIP, drug spending in the U.S. is projected to rise to $590 billion by 2020 from $337 billion in 2015.

Drug approvals by the U.S. Food and Drug Administration touched a 21-year high in 2017. Novel drug approvals by the FDA totaled 46 in 2017, up from 22 in the prior year.

Novel drugs are new molecular entities or NMEs having chemical structures that have never been approved before.

However, the exorbitant price tags for drugs have led to significant increases in health care spending and added to the growing financial strain faced by patients. The rising costs of drugs have angered patients and prompted key stakeholders to act.

Following a backlash over the high costs of many branded medicines, several drug makers have pledged to limit annual price hikes to under 10 percent.

Insurer UnitedHealthcare announced in early March that it will expand pharmacy discounts to more than 7 million people enrolled in its insured commercial group benefit plans.

The company said that when the policy is implemented starting next year, consumers will see lower out-of-pocket costs as they will be directly provided with savings from pharmacy manufacturer rebates at the time of purchase.

Below is a list by PharmaCompass of the top ten best-selling drugs in 2017, based on annual reports by the pharmaceutical companies.

Seven of last year’s ten top-selling drugs saw year-over-year sales gains, while the remaining three saw sales declines, reflecting the launch of generic competitors.